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Abstract
Aim: To evaluate the diagnostic and prognostic performance of alternative diagnostic 
strategies to oral glucose tolerance tests, including random plasma glucose, fasting 
plasma glucose and HbA1c, during the COVID-19 pandemic.
Methods: Retrospective service data (Cambridge, UK; 17 736 consecutive singleton 
pregnancies, 2004–2008; 826 consecutive gestational diabetes pregnancies, 2014–
2019) and 361 women with ≥1 gestational diabetes risk factor (OPHELIA prospective 
observational study, UK) were included. Pregnancy outcomes included gestational dia-
betes (National Institute of Health and Clinical Excellence or International Association 
of Diabetes and Pregnancy Study Groups criteria), diabetes in pregnancy (WHO crite-
ria), Caesarean section, large-for-gestational age infant, neonatal hypoglycaemia and 
neonatal intensive care unit admission. Receiver-operating characteristic curves and 
unadjusted logistic regression were used to compare random plasma glucose, fasting 
plasma glucose and HbA1c performance.
Results: Gestational diabetes diagnosis was significantly associated with random 
plasma glucose at 12 weeks [area under the receiver-operating characteristic curve for 
both criteria 0.81 (95% CI 0.79–0.83)], fasting plasma glucose [National Institute of 
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1 |  INTRODUCTION
Gestational diabetes mellitus (GDM) affects approximately 
5% of pregnant women in the UK and is associated with peri-
natal morbidity, including large-for-gestational-age (LGA) 
infants, complicated deliveries and neonatal hypoglycaemia.1 
The oral glucose tolerance test (OGTT) is currently the rec-
ommended approach to the diagnosis of GDM in the UK and 
internationally.2,3 Early in 2020, a novel virus, SARS-CoV-2, 
reached pandemic levels of worldwide infection.4 In the UK, 
pregnant women have been advised to remain in self-isolation 
for at least 12 weeks except for essential excursions for food, 
healthcare and health reasons (including outdoor daily exer-
cise), with similar restrictions internationally. This, alongside 
public transport limitations, especially during peak hours, 
social distancing and laboratory requirements, has made it 
challenging for healthcare providers to implement routine 
OGTTs. Furthermore, with staff shortages due to self-isola-
tion, illness or redeployment, the clinical capacity for manag-
ing large numbers of pregnant women with milder forms of 
hyperglycaemia has been reduced. An alternative approach 
to screening for severe forms of maternal hyperglycaemia 
during the COVID-19 pandemic was required for urgent im-
plementation.5 The intention was not aimed at identifying an 
equivalent group of women as those detected by OGTT, but 
rather to identify pregnant women with the highest glucose 
levels for whom specialist management remained essential 
throughout the pandemic. The alternative strategy recom-
mends glucose testing during other hospital or community 
appointments to minimize additional clinical contacts.5
The OGTT has well recognized limitations in terms of test 
reproducibility, tolerability and seasonal influences,6,7 but re-
mains the most commonly recommended diagnostic strategy 
for GDM.2,3 Excess fetal growth acceleration is detectable 
from 20 weeks’ gestation, predating diagnosis of GDM.8 
However, approximately half of women with identified risk 
factors for GDM, do not have an OGTT performed in rou-
tine care settings. Importantly, among women with stillbirths, 
an OGTT was only performed in 38% of women with GDM 
risk factors.9 A nationwide UK audit confirmed that OGTT 
testing was least likely to be performed in obese women 
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Health and Clinical Excellence: area under the receiver-operating characteristic curve 
0.75 (95% CI 0.65–0.85); International Association of Diabetes and Pregnancy Study 
Groups: area under the receiver-operating characteristic curve 0.92 (95% CI 0.85–0.98)] 
and HbA1c at 28 weeks' gestation [National Institute of Health and Clinical Excellence: 
0.83 (95% CI 0.75–0.90); International Association of Diabetes and Pregnancy Study 
Groups: 0.84 (95% CI 0.77–0.91)]. Each measure predicts some, but not all, pregnancy 
outcomes studied. At 12 weeks, ~5% of women would be identified using random 
plasma glucose ≥8.5 mmol/l (sensitivity 42%; specificity 96%) and at 28 weeks using 
HbA1c ≥39 mmol/mol (sensitivity 26%; specificity 96%) or fasting plasma glucose 
≥5.2–5.4 mmol/l (sensitivity 18–41%; specificity 97–98%).
Conclusions: Random plasma glucose at 12 weeks, and fasting plasma glucose or 
HbA1c at 28 weeks identify women with hyperglycaemia at risk of suboptimal preg-
nancy outcomes. These opportunistic laboratory tests perform adequately for risk strat-
ification when oral glucose tolerance testing is not available.
What's new?
• Screening procedures for hyperglycaemia in 
pregnancy have temporarily changed during the 
COVID-19 pandemic as oral glucose tolerance 
tests are challenging to conduct with social dis-
tancing measures in place, public transport restric-
tions and reduced clinical capacity.
• National recommendations for Australia, Canada, 
New Zealand and the UK propose alternative op-
portunistic screening strategies using HbA1c, ran-
dom plasma glucose and fasting plasma glucose 
(FPG), performed with routine antenatal bloods at 
booking and 28 weeks.
• We identified that random plasma glucose, HbA1c 
and FPG were all associated with gestational diabe-
tes diagnosis and that all three tests can predict ob-
stetric and neonatal outcomes but lack the evidence 
base and sensitivity of an oral glucose tolerance test.
• Future work should prioritize inclusive screening 
strategies which identify women at highest risk of 
materno-fetal complications and systematic proce-
dures for longer-term cardio-metabolic follow-up.
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and those from higher-risk ethnic groups.10 Although some 
women may refuse OGTT testing, it is clear that screening 
for GDM is not consistently implemented in accordance with 
guideline recommendations.6,10
A recent case–control study identified a 44% 
greater  risk of stillbirth  in women with risk factors when an 
OGTT was not performed.9 Likewise, women with raised fast-
ing plasma glucose (FPG) levels who were not diagnosed with 
GDM experienced a fourfold greater risk of stillbirth.9 Women 
who were appropriately screened and treated had no increased 
risk of stillbirth.9 This failure to effectively implement OGTT in 
routine clinical care settings even prior to the pandemic leaves 
women exposed to potentially modifiable risks for stillbirth.
Relatively little research has focused on identifying a 
suitable alternative to the OGTT. Some novel technologies 
and biomarkers show promise in small studies, but do not 
have proven diagnostic performance or wide availability. 
Performing an OGTT at home or replacing it with glucometer 
or continuous glucose monitoring readings was not feasible 
for widespread implementation during the pandemic.
The interim testing strategy for hyperglycaemia in preg-
nancy aimed to: (1) identify women with the most severe hy-
perglycaemia for prioritization of resources towards those at 
highest risk of suboptimal obstetric and neonatal outcomes; 
(2) fit around women’s routine antenatal visits at 12, 20 and 
28 weeks (for blood tests or ultrasound scans), avoiding 
additional visits to healthcare environments; (3) use estab-
lished laboratory methods with good analytical performance 
and wide availability; (4) avoid increasing clinical workload 
during staff shortage (prioritizing test specificity over sensi-
tivity); (5) be simple to understand (by non-specialists) and 
easy to rapidly implement across healthcare environments; 
and (6) use an existing evidence base to support it and to 
enable audit after the pandemic.
Several diagnostic strategies for hyperglycaemia in preg-
nancy have been suggested for use during the COVID-19 pan-
demic (Table 1). The UK approach advises measuring HbA1c 
and random plasma glucose in all women with risk factors 
for GDM (previous GDM, BMI >30 kg/m2, high-risk eth-
nic groups, family history of diabetes, previous macrosomic 
baby >4.5 kg) at the first antenatal visit (Table 4). Women 
with HbA1c levels ≥48 mmol/mol or random plasma glucose 
levels ≥11.1 mmol/l are managed as having pre-gestational, 
most commonly type 2 diabetes. Women with HbA1c levels 
41–47 mmol/mol or random plasma glucose levels 9–11.0 
mmol/l are managed as having early-onset GDM. Women 
with HbA1c <41 mmol/mol and random plasma glucose <9 
mmol/l are retested at 28 weeks, with a repeat HbA1c and FPG 
(if possible) or random plasma glucose performed. Women 
with FPG ≥5.6 mmol/l, HbA1c ≥39 mmol/mol or random 
plasma glucose ≥9 mmol/l are managed as having GDM. 
The pandemic testing procedures do not exclude GDM and 
further testing should be performed, at any gestational age, 
in women with glycosuria, symptoms of diabetes, or ultra-
sound features of LGA infant or polyhydramnios.5 Similar 
strategies were recommended in Australia, Canada and New 
Zealand (Table 1).11–13
The aim of the present study was to provide evidence-based 
recommendations for a pragmatic diagnostic strategy for hy-
perglycaemia in pregnancy, applicable during the COVID-19 
pandemic.
2 |  METHODS
Data from complete and ongoing studies (Table 2; methodol-
ogy and patient characteristics) were used to assess diagnostic 
performance of potential glucose measures including HbA1c, 
random plasma glucose, FPG and 1-h and 2-h plasma glucose 
after a 75-g OGTT performed in a real-world clinical setting.
Gestational diabetes diagnosis was classified according to 
the criteria of the UK National Institute for Health and Care 
Excellence (NICE; 0 min ≥5.6 mmol/l; 120 min ≥7.8 mmol/l)3 
and the International Association of Diabetes and Pregnancy 
Study Groups (IADPSG), adopted by the WHO (IADPSG/
WHO; 0 min ≥5.1; 60 min ≥10.0; 120 min ≥8.5 mmol/l)2.
Older (2004–2008) and more recent data (2014–2019) from 
approved service evaluations at Cambridge University Hospital 
NHS Foundation Trust (CUHFT) used for this study have been 
previously described.14,15 In brief, the older cohort includes 17 
736 consecutive women with singleton pregnancies, with ran-
dom plasma glucose performed at booking followed by a uni-
versal 50-g glucose challenge test at 24 weeks. Women with a 
50-g glucose challenge result of >7.7 mmol/l had a 75-g OGTT 
at 28 weeks’ gestation (n = 3848) and were offered treatment 
(776/17 736; 4.4%) in line with NICE guidance.16 A minority 
(<5%) had an OGTT using capillary rather than venous blood. 
The more recent cohort included 826 consecutive women with 
GDM (risk factor screening; 75-g OGTT 24–28 weeks using 
IADPSG/WHO criteria, 20 October 2014 to 31 January 2019), 
who received standard clinical management. Detailed informa-
tion on pregnancy outcomes was gathered from electronic med-
ical records as part of an ongoing service evaluation.14
In addition, data were included from 361 women with 
one or more risk factors for GDM,3 recruited from an ongo-
ing multicentre prospective study, OPHELIA (Observational 
study of Pregnancy Hyperglycaemia, Endocrine causes, Lipids, 
Insulin and Autoimmunity; REC 18/LO/0477; researchregistry 
no.5528). Briefly, women with a singleton pregnancy and one 
or more GDM risk factors3 were invited for a 24–28-week 75-g 
OGTT with measurement of HbA1c. A total of 8.3% of women 
had GDM (NICE criteria) and were offered treatment. Pregnancy 
outcome data from this ongoing study are not available.
Assessment of neonatal outcomes was performed using 
the older and recent CUHFT datasets. We chose outcomes 
which are directly related to hyperglycaemia, are consistently 
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measured during GDM pregnancies, are potentially modifi-
able by standard clinical management,1,17 and which have a 
defined impact on healthcare costs.3
Large for gestational age was defined as having a 
birth weight >90th centile using locally derived standard-
ized centiles adjusted for infant sex and gestational age.7 
T A B L E  2  Characteristics of women included in each dataset
Study characteristics
Older CUHFT cohort Recent CUHFT cohort OPHELIA cohort
n = 17736 n = 826 n = 361
Time period covered 2004–2008 2014–2019 Oct 2019–ongoing
Study design Retrospective service 
evaluation
Retrospective service 
evaluation
Prospective observational study
Population All singleton pregnancies 
with liveborn infants
All singleton pregnancies 
with GDM diagnosed 
according to IADPSG 
criteria
Singleton pregnancies with ≥1 
positive NICE risk factor
Centres Single centre Single centre Four East of England centres*
Who had a random plasma glucose at 12 
weeks?
All women offered, results 
available in 72%†
Not applicable Not applicable
Who had a 75-g OGTT at 24–28 weeks? Women with a 24-week 
50-g glucose challenge 
result >7.7 mmol/l
Women with ≥1 GDM risk 
factor
Women with ≥1 GDM risk 
factor
GDM diagnostic criteria 1998 WHO [31] IADPSG [2] NICE [3]
Treatment offered, n/N (%) 776/17736 (4.4) 826/826 (100) 30/331 (8.3)
Maternal characteristics
Mean (sd) maternal age years 30.9 (5.6) 33.6 (5.4) 31.7 (4.9)
Mean (sd) pre-pregnancy BMI, kg/m2 24.8 (5.0) 29.4 (7.5) 33.0 (6.7)
Primiparous, n (%) 9895 (56) 283 (34) 132 (37)
Ethnicity, n (%) n=670 n=345
White 15934 (90) 531 (79) 315 (91)
Black 258 (1.5) 14 (2.1) 29 (8.4)
Asian 899 (5.1) 111 (17) 1 (0.3)
Other 644 (3.6) 14 (2.1) 0 (0.0)
Maternal smoking, n (%) 1643 (9.3) 61/747 (8.2) N/A
Mean (sd) random plasma glucose mmol/l 
at 12 weeks, mmol/l
5.8 (1.4) N/A N/A
Mean (sd) HbA1c at 28 weeks, mmol/mol N/A 35.9 (4.9) 32.5 (3.6)
OGTT at 28 weeks n = 3848 n = 821–824 n = 359–360
Mean (sd) Fasting glucose (OGTT time 0) 4.5 (0.6) 4.9 (0.7) 4.4 (0.5)
Mean (sd) OGTT time 60 mins 8.5 (1.9) 10.6 (1.5) N/A
Mean (sd) OGTT time 120 mins 6.9 (1.6) 7.6 (1.4) 5.8 (1.4)
Pregnancy outcomes n = 17001–17736 n = 817-826 n = 278
Mean (sd) estimated gestational age at 
birth, weeks
39.2 (2.0) 38.5 (1.4) 39.4 (1.5)
LGA infant, n (%) 2112 (1) 134 (16) N/A
Caesarean section, n (%) 5005 (28) 342 (41) N/A
Neonatal hypoglycaemia, n (%) N/A 386 (47) N/A
NICU admission, n (%) 1071 (6.1) 124 (15) N/A
CUHFT, Cambridge University Hospital NHS Foundation Trust; FPG, fasting plasma glucose; LGA, large-for-gestational-age; NICU, neonatal intensive care unit.
Neonatal hypoglycaemia defined as neonatal glucose <2.6 mmol/l at least 4 h after birth. NICU admission defined as >24 h.
†No difference between women with and without a random plasma glucose.31 
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Neonatal hypoglycaemia was defined as a capillary blood 
glucose level <2.6 mmol/l on more than one occasion at 
least 4 h after birth. Admission to the neonatal intensive 
care unit (NICU) was defined as admission for 24 h or 
longer.
The ability of each glucose-related variable to predict 
GDM diagnosis was assessed using receiver-operating char-
acteristic (ROC) curves. Unadjusted logistic regression iden-
tified associations between glucose measures and pregnancy 
outcomes (odds ratios and 95% CIs reported). Missing data 
were not imputed. A statistical significance level of 5% was 
used throughout.
2.1 | Ethics
The OPHELIA study was approved by the London and 
Westminster research ethics committee (REC 18/LO/0477; 
research registry no.5528). The CUHFT data were collected 
as part of approved service evaluations. Further ethical ap-
proval was not required for this analysis.
3 |  RESULTS
3.1 | Prediction of gestational diabetes 
diagnosis and association with pregnancy 
outcomes
All glucose measures were significantly associated with 
GDM diagnosis on ROC curves (Table 3 and Fig. 1). 
Among the alternative glucose measures, HbA1c at 28 weeks 
and random plasma glucose at booking (12±2 weeks) both 
performed reasonably well, with areas under the ROC 
(AUROCs) of 0.83 (95% CI 0.75–0.90, OPHELIA) and 
0.81 (95% CI 0.79–0.83, older CUHFT cohort) to predict 
T A B L E  3  Associations between glucose measures, diagnosis of gestational diabetes and pregnancy outcomes
Study Population Total, n OGTT, n Design Outcome
Random plasma glucose
12 weeks
HbA1c
28 weeks
FPG
28 weeks
OGTT time 60
28 weeks
OGTT time 120
28 weeks
Diagnosis: receiver-operating characteristic curves AUROC (95% CI) AUROC (95% CI) AUROC (95%CI) AUROC (95%CI) AUROC (95%CI)
OPHELIA Antenatal population with ≥1 
GDM risk factor
361 361 Prospective NICE-GDM No data 0.83 (0.75--0.90)*** 0.75 (0.65-0.85)*** no data 0.93 (0.86-1.00)***
361 361 Prospective IADPSG-GDM No data 0.84 (0.77--0.91)*** 0.92 (0.85-0.98)*** no data 0.83 (0.75-0.92)***
Older CUHFT Antenatal population with 
positive glucose challenge 
test†
17736 3764 Retrospective NICE-GDM 0.81 (0.79--0.83)*** No data 0.69 (0.67-0.71)*** 0.83 (0.82-0.85)*** 0.99 (0.98-0.99)***
17736 3764 Retrospective IADPSG-GDM 0.81 (0.79--0.83)*** No data 0.79 (0.77-0.80)*** 0.93 (0.92-0.94)*** 0.85 (0.84-0.86)***
Diagnosis: unadjusted logistic regression OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI)
Older CUHFT Antenatal population with 
positive glucose challenge at 
24 weeks
17736 3764 Retrospective NICE-GDM 2.35 (2.24--2.46)*** No data 4.84 (4.13-5.67)*** 2.29 (2.16-2.44)*** 348.82 (200.76-
606.07)***
17736 3764 Retrospective IADPSG-GDM 2.45 (2.34--2.57)*** No data 16.00 (12.98-19.71)*** 5.76 (5.11-6.49)*** 3.66 (3.35-4.01)***
Recent CUHFT Women with ≥1 GDM risk factor
according to the IADPSG criteria
826 826 Prospective NICE-GDM No data n/a n/a no data n/a
826 826 Prospective IADPSG-GDM No data n/a n/a no data n/a
Pregnancy outcomes: unadjusted logistic regression OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Older CUHFT Antenatal population with 
positive glucose challenge at 
24 weeks
17736 3764 Retrospective LGA infant 1.10 (1.06--1.13)*** No data 1.87 (1.63-2.14)*** 1.11 (1.06-1.15)*** 1.04 (0.99-1.10)
17736 3764 Retrospective CS 1.15 (1.21-1.17)*** No data 1.48 (1.32-1.67)*** 1.10 (1.06-1.14)*** 1.11 (1.06-1.15)***
17736 3764 Retrospective NH No data No data No data No data No data
17736 3764 Retrospective NICU 1.06 (1.02-1.11)** No data 1.03 (0.82-1.28) 1.02 (0.95-1.10) 1.05 (0.97--1.14)
Recent CUHFT Women with ≥1 GDM risk factor
according to the IADPSG criteria
826 826 Prospective LGA infant no data 1.04 (1.00--1.08)* 1.28 (1.01--1.62)* No data 1.02 (0.92--1.14)
826 826 Prospective CS no data 1.04 (1.01--1.08)** 1.06 (0.88--1.28) No data 1.04 (0.95--1.13)
826 826 Prospective NH no data 1.05 (1.02--1.08)** 0.95 (0.79--1.15) No data 1.00 (0.92--1.08)
826 826 Prospective NICU no data 1.02 (0.98--1.06) 1.21 (0.94--1.54) No data 0.93 (0.83--1.04)
AUROC, area under the receiver-operating characteristic curve; CS, Caesarean section; CUHFT, Cambridge University Hospital NHS Foundation Trust; FPG,  
fasting plasma glucose; GDM, gestational diabetes; IADPSG, International Association of Diabetes and Pregnancy Study Groups; LGA, large-for-gestational-age;  
NICE, National Institute for Health and Care Excellence; NICU, neonatal intensive care unit; NH, neonatal hypoglycaemia; NICU. neonatal intensive care unit; OR, odds ratio.
NH defined as neonatal glucose <2.6 mmol/l at least 4 h after birth. NICU admission defined as >24 h. OPHELIA included 361 women (8.3% with NICE-defined  
GDM) all offered standard clinical management. Older CUHFT data included 4.3% of women (4.5% using current NICE GDM criteria) offered standard clinical  
management. The recent CUHFT data includes women with IADPSG-defined GDM, all of whom were offered standard clinical management. ORs were calculated  
using continuous measures. *P < 0.05; **P<0.01; ***P<0.001. †Glucose >7.8 mmol/l, 1 h after a universal 50-g glucose challenge at 24 weeks' gestation.
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NICE-defined GDM.4 The AUROC for random plasma glu-
cose at booking was comparable for GDM as defined ether 
by NICE or IADPSG criteria. FPG was slightly less predic-
tive for GDM defined by the NICE criteria [AUROC 0.75 
(95% CI 0.65–0.85), OPHELIA], but strongly predicted 
GDM defined according to the IADPSG criteria [AUROC 
0.92 (95% CI 0.85–0.98) OPHELIA]. All glucose measures 
studied had associations with one or more outcomes (Table 
3).
3.2 | Assessment of potential thresholds
The sensitivity and specificity of thresholds for random 
plasma glucose, HbA1c and FPG to predict GDM using 
NICE or IADPSG diagnostic criteria are given in Table 
4. For example, to identify a similar proportion of women 
as detected by the NICE criteria (~5%) would require a 
12-week random plasma glucose of ≥8.5 mmol/l (42% 
sensitivity, 96% specificity; older CUHFT cohort), a 28-
week HbA1c of ≥39 mmol/mol (26% sensitivity, 96% 
specificity; OPHELIA); or an FPG of ≥5.2–5.4 mmol/l 
(sensitivity 18–41%, specificity 97–98%; OPHELIA or 
older CUHFT).
3.3 | Predictors for diabetes in pregnancy
Fasting plasma glucose at 28 weeks was the best predictor 
of diabetes in pregnancy [AUROC 0.9 (95% CI 0.86–0.95); 
older CUHFT), with a specificity of >90% and sensitiv-
ity of 50–70% at thresholds of ≥5.2 mmol/l (Table S1). 
Unfortunately, the number of women with HbA1c >48 
mmol/mol was not available and the number with IADPSG-
defined ‘overt diabetes’ was too small (n = 19) to draw any 
conclusions.
T A B L E  3  Associations between glucose measures, diagnosis of gestational diabetes and pregnancy outcomes
Study Population Total, n OGTT, n Design Outcome
Random plasma glucose
12 weeks
HbA1c
28 weeks
FPG
28 weeks
OGTT time 60
28 weeks
OGTT time 120
28 weeks
Diagnosis: receiver-operating characteristic curves AUROC (95% CI) AUROC (95% CI) AUROC (95%CI) AUROC (95%CI) AUROC (95%CI)
OPHELIA Antenatal population with ≥1 
GDM risk factor
361 361 Prospective NICE-GDM No data 0.83 (0.75--0.90)*** 0.75 (0.65-0.85)*** no data 0.93 (0.86-1.00)***
361 361 Prospective IADPSG-GDM No data 0.84 (0.77--0.91)*** 0.92 (0.85-0.98)*** no data 0.83 (0.75-0.92)***
Older CUHFT Antenatal population with 
positive glucose challenge 
test†
17736 3764 Retrospective NICE-GDM 0.81 (0.79--0.83)*** No data 0.69 (0.67-0.71)*** 0.83 (0.82-0.85)*** 0.99 (0.98-0.99)***
17736 3764 Retrospective IADPSG-GDM 0.81 (0.79--0.83)*** No data 0.79 (0.77-0.80)*** 0.93 (0.92-0.94)*** 0.85 (0.84-0.86)***
Diagnosis: unadjusted logistic regression OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI)
Older CUHFT Antenatal population with 
positive glucose challenge at 
24 weeks
17736 3764 Retrospective NICE-GDM 2.35 (2.24--2.46)*** No data 4.84 (4.13-5.67)*** 2.29 (2.16-2.44)*** 348.82 (200.76-
606.07)***
17736 3764 Retrospective IADPSG-GDM 2.45 (2.34--2.57)*** No data 16.00 (12.98-19.71)*** 5.76 (5.11-6.49)*** 3.66 (3.35-4.01)***
Recent CUHFT Women with ≥1 GDM risk factor
according to the IADPSG criteria
826 826 Prospective NICE-GDM No data n/a n/a no data n/a
826 826 Prospective IADPSG-GDM No data n/a n/a no data n/a
Pregnancy outcomes: unadjusted logistic regression OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Older CUHFT Antenatal population with 
positive glucose challenge at 
24 weeks
17736 3764 Retrospective LGA infant 1.10 (1.06--1.13)*** No data 1.87 (1.63-2.14)*** 1.11 (1.06-1.15)*** 1.04 (0.99-1.10)
17736 3764 Retrospective CS 1.15 (1.21-1.17)*** No data 1.48 (1.32-1.67)*** 1.10 (1.06-1.14)*** 1.11 (1.06-1.15)***
17736 3764 Retrospective NH No data No data No data No data No data
17736 3764 Retrospective NICU 1.06 (1.02-1.11)** No data 1.03 (0.82-1.28) 1.02 (0.95-1.10) 1.05 (0.97--1.14)
Recent CUHFT Women with ≥1 GDM risk factor
according to the IADPSG criteria
826 826 Prospective LGA infant no data 1.04 (1.00--1.08)* 1.28 (1.01--1.62)* No data 1.02 (0.92--1.14)
826 826 Prospective CS no data 1.04 (1.01--1.08)** 1.06 (0.88--1.28) No data 1.04 (0.95--1.13)
826 826 Prospective NH no data 1.05 (1.02--1.08)** 0.95 (0.79--1.15) No data 1.00 (0.92--1.08)
826 826 Prospective NICU no data 1.02 (0.98--1.06) 1.21 (0.94--1.54) No data 0.93 (0.83--1.04)
AUROC, area under the receiver-operating characteristic curve; CS, Caesarean section; CUHFT, Cambridge University Hospital NHS Foundation Trust; FPG,  
fasting plasma glucose; GDM, gestational diabetes; IADPSG, International Association of Diabetes and Pregnancy Study Groups; LGA, large-for-gestational-age;  
NICE, National Institute for Health and Care Excellence; NICU, neonatal intensive care unit; NH, neonatal hypoglycaemia; NICU. neonatal intensive care unit; OR, odds ratio.
NH defined as neonatal glucose <2.6 mmol/l at least 4 h after birth. NICU admission defined as >24 h. OPHELIA included 361 women (8.3% with NICE-defined  
GDM) all offered standard clinical management. Older CUHFT data included 4.3% of women (4.5% using current NICE GDM criteria) offered standard clinical  
management. The recent CUHFT data includes women with IADPSG-defined GDM, all of whom were offered standard clinical management. ORs were calculated  
using continuous measures. *P < 0.05; **P<0.01; ***P<0.001. †Glucose >7.8 mmol/l, 1 h after a universal 50-g glucose challenge at 24 weeks' gestation.
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4 |  DISCUSSION
There are limited data available to support a change in di-
agnostic criteria for GDM in a real-world clinical setting. 
Despite this, our results provide some evidence regarding the 
use of routine antenatal blood tests, random plasma glucose 
at 12 weeks' gestation and HbA1c or FPG at 28 weeks' gesta-
tion for diagnosing hyperglycaemia in pregnancy during the 
COVID-19 pandemic.5 These established, affordable, widely 
available laboratory tests have reasonable ability to predict 
diagnosis of GDM and to identify women at highest risk 
of suboptimal glycaemic, obstetric and neonatal outcomes. 
F I G U R E  1  Receiver-operating characteristic curves for (A & B) HbA1c at 28 weeks, (C & D) random plasma glucose at booking and fasting 
plasma glucose (FPG) at 28 weeks for predicting gestational diabetes diagnosis according to NICE and IADPSG criteria.
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Although the sensitivity of these measures is substantially 
lower than that of the OGTT, the specificity is sufficient to 
allow targeted assessment of women at highest risk.
Despite differences between the universal and selective 
risk factor screening procedures and patient characteristics, 
the results show consistent associations between routine 
antenatal glucose measures, GDM diagnosis and clinically 
relevant obstetric and neonatal outcomes (Caesarean deliv-
ery, LGA infant, neonatal hypoglycaemia, neonatal intensive 
care unit admission). However, the women included in the 
present study were not blinded to their diagnosis, had GDM 
diagnosed using different screening pathways and diagnos-
tic criteria, and had no measures of glycaemic control later 
in pregnancy. The treatment of patients within these clinical 
datasets will not affect diagnostic predictions but may have re-
duced associations with maternal or neonatal outcomes. The 
use of unadjusted regression reflects clinical decision-mak-
ing; adjusted odds ratios may show different associations. In 
addition, these datasets do not have sufficient ethnic diversity 
to fully represent national or international populations, with 
more women belonging to higher-risk ethnic groups. The 
older CUHFT dataset is large but not all women underwent 
an OGTT to exclude GDM and none of the datasets used 
universal screening for GDM with an OGTT at 28 weeks. 
These results reflect test performance in high-risk cohorts. 
The OPHELIA study reflects a high-risk cohort, chosen ac-
cording to risk factors3 (UK approach), while the older CUH 
cohort reflects a high-risk cohort chosen from a two-step 
strategy (used widely in USA).5 Although these results are 
not directly comparable to assessments of test performance 
in an unselected population, they are comparable to current 
clinical practice internationally. Although preventing still-
birth is a priority during the pandemic, as this outcome is 
so rare, the datasets provide insufficient data to allow this 
outcome to be assessed accurately.
Compared to an OGTT, random plasma glucose, HbA1c 
and FPG assessments have less evidence to support their 
use in the diagnosis of GDM. The ability of a first-trimes-
ter OGTT to predict pregnancy outcomes is also unclear. 
However, random plasma glucose performs surprisingly well 
as a first-trimester predictive tool for later GDM diagnosis.15 
An early-pregnancy random plasma glucose also has consis-
tent associations with Caesarean section, LGA infant, and 
neonatal intensive care unit admission, but the small odds 
ratios suggest that random plasma glucose alone lacks pre-
cision as a prognostic tool. The performance of and optimal 
thresholds for random plasma glucose in late pregnancy are 
unknown. Random plasma glucose was included pragmati-
cally, alongside routine bloods, to minimize the logistical 
challenges associated with obtaining multiple early-morning 
fasted samples within a short timeframe.
Fasting plasma glucose assessment, when performed 
as part of an OGTT at 24–28 weeks' gestation, has strong 
associations with the pregnancy outcomes attributed to fetal 
hyperinsulinism including primary Caesarean delivery, LGA 
infant and neonatal hypoglycaemia.18 The necessity of hav-
ing a test in the fasting state, and therefore in the morning, is 
associated with non-attendance.6 This was pertinent during 
the pandemic peak, when having all women attend during a 
small, timeframe was logistically difficult, and challenging 
for women without private transport. More data are required 
to better understand whether the requirement for an overnight 
fast and early-morning attendance influences uptake of the 
OGTT, especially among socially disadvantaged women in 
real-world clinical settings6
Unfortunately, although included in the UK, Canadian, 
Australian and New Zealand recommendations5,11–13 to de-
tect overt and/or pre-gestational diabetes, we did not have 
data for HbA1c in early pregnancy. Hughes et al.
19 previously 
demonstrated that an early-pregnancy HbA1c ≥ 41 mmol/
mol (5.9%) was predictive for diabetes and for identifying 
mothers and offspring at risk of complications.19 In the pres-
ent study, we found that HbA1c ≥39 mmol/mol (5.7%) at 28 
weeks' gestation had good specificity (96%) and identified 
approximately 5% of women who were screened, a compa-
rable number to those identified using the NICE or IADPSG 
criteria.3,4 Outside pregnancy, HbA1c is widely used both for 
diabetes diagnosis and glycaemic monitoring, and is highly 
predictive of diabetes complications.20,21 However, accuracy 
is reliant on stable red cell turnover and the absence of haema-
tological disease, iron deficiency or inherited haemoglobin 
variants.21,22 In early pregnancy, red cell turnover increases, 
contributing to the well-recognized non-glycaemic reduction 
in HbA1c in the late first/early second trimesters.
21 HbA1c is 
therefore a poor marker for individual glycaemia, but remains 
important for predicting obstetric and neonatal outcomes in-
cluding preterm delivery, LGA infant and neonatal intensive 
care unit admission.23 The proposed screening strategy in-
cludes an early HbA1c measurement to exclude overt diabe-
tes and a 28-week measurement for pragmatic reasons, with 
interpretation in conjunction with another glucose measure, 
either FPG or random plasma glucose.
Although the OGTT is the most widely used test for GDM 
diagnosis, this recommendation is largely based on research 
data with optimal pre-analytical processing and analytical per-
formance within specialist laboratory settings.30 The OGTT 
has poor reproducibility in real-world clinical settings.24 Non-
pregnant individuals having two OGTTs within 1 week receive 
the same diagnosis of diabetes, prediabetes, or normal glucose 
tolerance on 27–80% of occasions.25 FPG values can vary by 
10–30% in adults with normal glucose tolerance.25 The intra-in-
dividual variation in OGTT glucose is predominantly deter-
mined by biological variation in normoglycaemic adults, with 
95% of the test–retest variability of <15% for FPG and <46% 
for 2-h post OGTT glucose.26 The diagnostic performance of 
an OGTT is pertinent during pregnancy, where substantial 
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variability was described by O’Sullivan et al.27 more than 50 
years ago. More recently, seasonal differences in OGTT per-
formance have been highlighted: higher ambient temperatures 
may increase GDM diagnosis by ~30% in the UK summer.7 
Pre-analytical processing is also critical: a recent Australian 
study reported that early centrifugation (<10 min) was associ-
ated with almost a doubling in GDM diagnoses.24
A Canadian study found that almost 50% of women with 
GDM diagnosed using an OGTT were normoglycaemic 
using capillary glucose monitoring in daily life, emphasizing 
concerns about sensitivity.28 Continuous glucose monitoring 
reflects fetal exposure to maternal glycaemia during the 24-h 
day, providing substantially more detailed glucose measure-
ments compared to an OGTT or capillary glucose monitor-
ing. Preliminary data have identified the continuous glucose 
monitoring glucose profiles associated with LGA infants in 
women with GDM, although further research is needed to 
determine the feasibility and performance of continuous glu-
cose monitoring for GDM diagnosis.29
Despite its limitations, the OGTT has a strong evidence 
base in the diagnosis of GDM.18 The Hyperglycaemia and 
Adverse Pregnancy Outcomes (HAPO) study demonstrated 
consistent linear associations between maternal glucose con-
centrations during an OGTT with pregnancy outcomes.18 
Furthermore, the OGTT identifies women who gain demon-
strable benefit from standard clinical management, with 
reductions in adverse pregnancy outcomes in women with 
more severe hyperglycaemia and improvements in maternal 
infant metabolic outcomes in women with ‘milder’ GDM 
confirmed by high-quality randomized controlled trial data.1
The COVID-19 pandemic has prompted a review of 
procedures for the screening and diagnosis of hypergly-
caemia during pregnancy. Stacey et al.9 have demonstrated 
no increase in stillbirth for women who are appropriately 
screened by OGTT and treated, but screening procedures 
are variably implemented and many high-risk women are 
not screened. The HAPO follow-up study highlights the 
longer-term impact of antenatal hyperglycaemia on the 
risks of overweight, obesity and diabetes in both mother 
and child.30 Women who are appropriately screened and 
managed for GDM can now have pregnancy outcomes 
comparable to the background maternity population, but 
we lack contemporary data on their progression to type 
2 diabetes and/or the longer-term cardio-metabolic out-
comes. After the pandemic, larger population-based 
studies should seek to evaluate whether the compliance 
benefits of having opportunistic tests such as HbA1c and 
random plasma glucose performed in routine antenatal care 
settings can reduce the risks of perinatal death, especially 
among women in socially disadvantaged and higher-risk 
ethnic groups. Various diagnostic thresholds at booking 
and at 28 weeks should be examined (separately and in 
combination) in relation to pregnancy outcomes alongside 
longer-term cardio-metabolic follow-up programmes for 
women with treated GDM and their offspring.
In conclusion, the proposed changes to testing for hypergly-
caemia during pregnancy facilitate identification of women at 
highest risk during the COVID-19 pandemic peak, but should not 
be adopted long-term. Future work should aim to identify prag-
matic, evidence-based alternatives to the OGTT, document the 
risks and benefits of opportunistic glycaemic testing in women 
from marginalized patient populations, and address longer-term 
maternal and childhood cardio-metabolic health outcomes.
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